{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:04:20Z","timestamp":1773234260326,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T00:00:00Z","timestamp":1175558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T00:00:00Z","timestamp":1175558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1038\/sj.pcan.4500939","type":"journal-article","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T07:22:40Z","timestamp":1175584960000},"page":"396-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation"],"prefix":"10.1038","volume":"10","author":[{"given":"S","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C G","family":"Silliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D L","family":"Trump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,4,3]]},"reference":[{"key":"BF4500939_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bjc.1996.416","volume":"74","author":"V Dieras","year":"1996","unstructured":"Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL et al. A multicentre phase II study of docetaxel 75\u2009mg\u2009m\u22122 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 1996; 74: 650\u2013656.","journal-title":"Br J Cancer"},{"key":"BF4500939_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O\u2019Rourke M et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095\u20132103.","journal-title":"J Clin Oncol"},{"key":"BF4500939_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00000421-200008000-00005","volume":"23","author":"D Mavroudis","year":"2000","unstructured":"Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000; 23: 341\u2013344.","journal-title":"Am J Clin Oncol"},{"key":"BF4500939_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502\u20131512.","journal-title":"N Engl J Med"},{"key":"BF4500939_CR5","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","volume":"13","author":"V Valero","year":"1995","unstructured":"Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886\u20132894.","journal-title":"J Clin Oncol"},{"key":"BF4500939_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/00000421-200004000-00006","volume":"23","author":"V Ferraresi","year":"2000","unstructured":"Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nistico C et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol 2000; 23: 132\u2013139.","journal-title":"Am J Clin Oncol"},{"key":"BF4500939_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S0161-6420(00)00640-0","volume":"108","author":"B Esmaeli","year":"2001","unstructured":"Esmaeli B, Valero V, Ahmadi MA, Booser D . Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001; 108: 994\u2013995.","journal-title":"Ophthalmology"},{"key":"BF4500939_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0161-6420(80)35250-0","volume":"87","author":"HD Perry","year":"1980","unstructured":"Perry HD, Serniuk RA . Conservative treatment of chalazia. Ophthalmology 1980; 87: 218\u2013221.","journal-title":"Ophthalmology"},{"key":"BF4500939_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/archopht.120.9.1180","volume":"120","author":"B Esmaeli","year":"2002","unstructured":"Esmaeli B, Ahmadi MA, Rivera E, Valero V, Hutto T, Jackson DM et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120: 1180\u20131182.","journal-title":"Arch Ophthalmol"},{"key":"BF4500939_CR10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S0161-6420(02)00989-2","volume":"109","author":"B Esmaeli","year":"2002","unstructured":"Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002; 109: 1188\u20131191.","journal-title":"Ophthalmology"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/4500939.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4500939","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4500939.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:38:50Z","timestamp":1648679930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/4500939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,3]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["BF4500939"],"URL":"https:\/\/doi.org\/10.1038\/sj.pcan.4500939","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,3]]},"assertion":[{"value":"21 September 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}